Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome

2013 ◽  
Vol 100 (3) ◽  
pp. S348 ◽  
Author(s):  
C.S. Atabekoglu ◽  
Y.E. Sükür ◽  
K. Kahraman ◽  
B. Özmen ◽  
M. Sönmezer ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Polycystic Ovary Syndrome ◽  
Cyproterone Acetate ◽  
Polycystic Ovary ◽  
Ovary Syndrome

Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate

2011 ◽  
Vol 27 (12) ◽  
pp. 971-977 ◽  
Author(s):  
George Markantes ◽  
Alexandros D. Saltamavros ◽  
Vasiliki Vervita ◽  
Anastasia K. Armeni ◽  
Anastasia Karela ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Polycystic Ovary Syndrome ◽  
Young Women ◽  
Cyproterone Acetate ◽  
Ethinyl Estradiol ◽  
Polycystic Ovary ◽  
Plasma Viscosity ◽  
Ovary Syndrome

The metabolic effects of metformin, cyproterone-acetate and their combination in women with polycystic ovary syndrome

2019 ◽  
Author(s):  
Ivana Bozic-Antic ◽  
Dusan Ilic ◽  
Tamara Bogavac ◽  
Snjezana Erceg ◽  
Mirjana Lacmanovic ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Cyproterone Acetate ◽  
Polycystic Ovary ◽  
Metabolic Effects ◽  
Ovary Syndrome

Circulating gut microbiota metabolite trimethylamine N‐oxide and oral contraceptive use in polycystic ovary syndrome

2019 ◽  
Vol 91 (6) ◽  
pp. 810-815 ◽  
Author(s):  
Nesrin Damla Eyupoglu ◽  
Ezgi Caliskan Guzelce ◽  
Aylin Acikgoz ◽  
Esra Uyanik ◽  
Bodil Bjørndal ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Polycystic Ovary Syndrome ◽  
Gut Microbiota ◽  
Contraceptive Use ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Oral Contraceptive Use
Sign in / Sign up

Export Citation Format

Share Document